We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Thermo Fisher Scientific to Acquire Transplant Diagnostics Leader One Lambda

By LabMedica International staff writers
Posted on 18 Jul 2012
Print article
Thermo Fisher Scientific (Waltham, MA, USA) has signed a definitive agreement to acquire One Lambda (Canoga Park, CA, USA), pioneer and global leader in transplant diagnostics, for USD 925 million in cash. One Lambda, whose business generated revenue of USD 182 million in 2011, will become part of Thermo Fisher’s Specialty Diagnostics Segment.

One Lambda develops its own transplant diagnostic tests utilizing serological, molecular, ELISA, flow, and Luminex xMAP technologies. The company also manufactures laboratory instrumentation and computer software that are used to simplify and automate testing procedures and final test evaluations. The transaction is expected enhance Thermo Fisher's presence in specialty in vitro diagnostics as growth in transplant diagnostics is being driven by increasing global demand. The specialized technology supports a broad portfolio of high-margin reagents in HLA (human leukocyte antigen) typing and antibody detection. New workflow capabilities will be added, as One Lambda's pre- and posttransplant tests will complement Thermo Fisher’s existing immunosuppressant assays. Thermo Fisher expects to leverage its extensive commercial capabilities to accelerate growth in One Lambda’s existing portfolio, which is currently marketed primarily to physicians and laboratories in the USA.

"With its strong technology platform, high margin profile, and good growth prospects, the business is perfectly aligned with our specialty in vitro diagnostics strategy," said Marc N. Casper, president, and chief executive officer of Thermo Fisher. George M. Ayoub, cofounder, president, and chief executive officer of One Lambda, added "I believe that, together, we will […] accelerate growth and improve the success rate of transplantation."

The transaction, anticipated for completion in the fourth quarter of 2012, is expected to be immediately accretive upon close and to generate revenue and cost synergies for a total adjusted operating income benefit of approximately USD 15 million in 2015. Thermo Fisher also announced an authorization to repurchase an additional USD 500 million of shares of its own common stock. “The acquisition of One Lambda […] demonstrates our ongoing commitment to effectively deploying our capital to create shareholder value,” Casper said.

Related Links:

Thermo Fisher Scientific, Inc.
One Lambda, Inc.




Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.